Drugs / Ag85B-ESAT-6
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01049282 | Dec 2008 → Apr 2010 | tuberculosis | Statens Serum Institut | Completed | No outcome recorded |
| Phase 1 | NCT00929396 | Sep 2007 → Jun 2009 | tuberculosis | Statens Serum Institut | Completed | No outcome recorded |
| Phase 1 | NCT01003093 | Nov 2005 → Mar 2008 | tuberculosis | Statens Serum Institut | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00922363 Background | Oct 2009 → Oct 2011 | tuberculosis | Statens Serum Institut | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ag85B-ESAT-6 | “In the present study, we monitored safety and IFN-γ responses in healthy BCG-vaccinated and prior or latently TB-infected individuals receiving a novel vaccine composed of the...” PMID 21256189 ↗ Jan 20113“the fusion protein Ag85B-ESAT-6, administered at 0 and 2 months either as recombinant protein alone or combined with two concentrations of the novel adjuvant IC31” PMID 20226890 ↗ Mar 2010 |
| Modality | Vaccine | “Tuberculosis Subunit Vaccine Ag85B-ESAT-6” NCT00922363 ↗ |
| Route | Other | “o,5 mL suspension for injection x 2 with 2 months interval” NCT00929396 ↗ |